Lentigen has 3 programs that are approaching clinical trials. LG690 is a treatment for Graft vs Host Disease. LG631 is a treatment for Glioma (brain cancer). LG889 is a treatment for Hemophilia A. LG690 and LG631 will enter phase I clinical trials in 2009. LG889 will likely enter phase I clinical testing in 2010.